Literature DB >> 11861328

Constitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix seven.

Séverine Barroso1, Françoise Richard, Delphine Nicolas-Ethève, Patrick Kitabgi, Catherine Labbé-Jullié.   

Abstract

1. The neurotensin receptor 1, NTS1, is a G protein-coupled receptor with seven transmembrane domains (TM) that mediates most of the known effects of the neuropeptide. Our previous studies have pointed to extracellular loop 3 and adjacent TM7 as being potentially involved in agonist-induced activation of the NTS1. 2. Here we investigated residues in these domains that might be involved in transconformational activation of the rat NTS1. Single amino acid mutated receptors were expressed in COS cells and inositol phosphate (IP) and cyclic AMP productions were studied. 3. The F358A mutation in TM7 resulted in a time- and receptor concentration-dependent increase in spontaneous IP production. At expression levels of 12 pmol mg(-1), agonist-independent IP production was increased 10 fold over basal for the F358A mutant receptor whereas the wild type NTS1 exhibited virtually no spontaneous activity at expression levels of 7.5 pmol mg(-1). 4. Neurotensin remained agonist on the F358A mutant receptor with a maximal effect that amounted to greater than twice basal IP levels. SR 48692 was inverse agonist at the mutant receptor, reversing IP production almost back to the levels measured in wild type NTS1-transfected cells. 5. Cyclic AMP production was not constitutively activated with the F358A mutant receptor but was stimulated by neurotensin with the same concentration dependence as that observed with the wild type NTS1. 6. This is the first report, to our knowledge, of a constitutively active mutant of the NTS1. The data are consistent with TM7 being involved in the transconformational changes that lead to agonist-induced coupling of the NTS1 to Gq.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861328      PMCID: PMC1573210          DOI: 10.1038/sj.bjp.0704546

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands.

Authors:  M Valiquette; H K Vu; S Y Yue; C Wahlestedt; P Walker
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

2.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

3.  Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor.

Authors:  M M Rosenkilde; T W Schwartz
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

4.  Mechanism of activation and inactivation of opsin: role of Glu113 and Lys296.

Authors:  G B Cohen; D D Oprian; P R Robinson
Journal:  Biochemistry       Date:  1992-12-22       Impact factor: 3.162

5.  Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line.

Authors:  J N Bidard; F de Nadai; C Rovere; D Moinier; J Laur; J Martinez; J C Cuber; P Kitabgi
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

6.  Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells.

Authors:  M Yamada; M Yamada; M A Watson; E Richelson
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

7.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

Authors:  D Gully; M Canton; R Boigegrain; F Jeanjean; J C Molimard; M Poncelet; C Gueudet; M Heaulme; R Leyris; A Brouard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

8.  Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling.

Authors:  T Nanevicz; L Wang; M Chen; M Ishii; S R Coughlin
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

9.  Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.

Authors:  J Parma; J Van Sande; S Swillens; M Tonacchera; J Dumont; G Vassart
Journal:  Mol Endocrinol       Date:  1995-06

10.  Inverse agonist activity of beta-adrenergic antagonists.

Authors:  P Chidiac; T E Hebert; M Valiquette; M Dennis; M Bouvier
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

View more
  11 in total

Review 1.  Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.

Authors:  Louis M Luttrell
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

2.  Engineering G protein-coupled receptor expression in bacteria.

Authors:  Georgios Skretas; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

3.  Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity.

Authors:  Casim A Sarkar; Igor Dodevski; Manca Kenig; Stefan Dudli; Anja Mohr; Emmanuel Hermans; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

Review 4.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

5.  Structure of the agonist-bound neurotensin receptor.

Authors:  Jim F White; Nicholas Noinaj; Yoko Shibata; James Love; Brian Kloss; Feng Xu; Jelena Gvozdenovic-Jeremic; Priyanka Shah; Joseph Shiloach; Christopher G Tate; Reinhard Grisshammer
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

6.  Thermostabilization of the neurotensin receptor NTS1.

Authors:  Yoko Shibata; Jim F White; Maria J Serrano-Vega; Francesca Magnani; Amanda L Aloia; Reinhard Grisshammer; Christopher G Tate
Journal:  J Mol Biol       Date:  2009-05-05       Impact factor: 5.469

7.  Rapid Computational Prediction of Thermostabilizing Mutations for G Protein-Coupled Receptors.

Authors:  Supriyo Bhattacharya; Sangbae Lee; Reinhard Grisshammer; Christopher G Tate; Nagarajan Vaidehi
Journal:  J Chem Theory Comput       Date:  2014-10-14       Impact factor: 6.006

8.  Structure and dynamics of a constitutively active neurotensin receptor.

Authors:  Brian E Krumm; Sangbae Lee; Supriyo Bhattacharya; Istvan Botos; Courtney F White; Haijuan Du; Nagarajan Vaidehi; Reinhard Grisshammer
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

9.  Dynamic tuneable G protein-coupled receptor monomer-dimer populations.

Authors:  Patricia M Dijkman; Oliver K Castell; Alan D Goddard; Juan C Munoz-Garcia; Chris de Graaf; Mark I Wallace; Anthony Watts
Journal:  Nat Commun       Date:  2018-04-27       Impact factor: 14.919

10.  Optimising the combination of thermostabilising mutations in the neurotensin receptor for structure determination.

Authors:  Yoko Shibata; Jelena Gvozdenovic-Jeremic; James Love; Brian Kloss; Jim F White; Reinhard Grisshammer; Christopher G Tate
Journal:  Biochim Biophys Acta       Date:  2013-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.